DYV 024
Alternative Names: DYV-024Latest Information Update: 12 Nov 2022
At a glance
- Originator Dyve Biosciences
- Class Antipsoriatics; Skin disorder therapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Psoriasis
Most Recent Events
- 03 Nov 2022 Preclinical trials in Psoriasis in USA (Transdermal)(Dyve Biosciences Pipeline, November 2022)
- 03 Nov 2022 Dyve plans a proof-of-concept trial for Psoriasis in USA (Dyve Biosciences Pipeline, November 2022)